system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adult, Aged, Analysis of Variance, Biomarkers, Tumor, Chromatin, DNA, Databases, Factual, Dilatation and Curettage, Endometrial Neoplasms, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Norway, Ploidies, Predictive Value of Tests, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Specimen Handling, Survival Rate.
user
Does changes in chromatin structure in curettage specimens identify high-risk patients in endometrial cancer? Context: Most endometrial carcinoma patients are diagnosed at an early stage with a good prognosis. However, a relatively low fraction with lethal disease constitutes a substantial number of patients due to the high incidence rate. Preoperative identification of patients with high-risk and low-risk for poor outcome is necessary to tailor treatment. Nucleotyping refers to characterisation of cell nuclei by image cytometry, including the assessment of chromatin structure by nuclear texture analysis. This method is a strong prognostic marker in many cancers, but has not been evaluated in preoperative curettage specimens from endometrial carcinoma. The prognostic impact of changes in chromatin structure quantified with Nucleotyping was evaluated in preoperative curettage specimens from 791 endometrial carcinoma patients prospectively included in the MoMaTEC multicentre trial. Nucleotyping was an independent prognostic marker of disease-specific survival in preoperative curettage specimens among patients with FIGO stage I-II disease (HR=2.9 (1.2-6.5), p=0.013), and significantly associated with age, FIGO stage, histologic type, histologic grade, myometrial infiltration, lymph node status, curettage histology type and DNA ploidy.
assistant
Nucleotyping in preoperative curettage specimens is an independent prognostic marker for disease-specific survival, with potential to supplement existing parameters for risk stratification to tailor treatment. Final Decision: yes